Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress
May 12, 2021 on track for
Phase III European trial in stage IIIB/C melanoma. Opening of additional clinical centers to boost recruitment rate is ongoing. E
Fibromun
Philogen is well capitalized, about
th the
here (https://us06web.zoom.us/webinar/register/WN nEuoFxsHTXSTdtS4RBslYg)
Siena (Italy), 12 May 2021 - (Globe Newswire) - Philogen S.p.A. (BIT:PHIL) - a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to announce progress updates for its fully-owned immunocytokine and small molecule programs.